Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation


Lynch syndrome (LS) predisposes to a spectrum of cancers and increases the lifetime risk of developing colorectal- or endometrial cancer to over 50%. Lynch syndrome is dominantly inherited and is caused by defects in DNA mismatch-repair genes MLH1, MSH2, MSH6 or PMS2, with the vast majority detected in MLH1 and MSH2. Recurrent LS-associated variants observed in apparently unrelated individuals, have either arisen de novo in different families due to mutation hotspots, or are inherited from a founder (a common ancestor) that lived several generations back. There are variants that recur in some populations while also acting as founders in other ethnic groups. Testing for founder mutations can facilitate molecular diagnosis of Lynch Syndrome more efficiently and more cost effective than screening for all possible mutations. Here we report a study of the missense mutation MLH1 c.2059C > T (p.Arg687Trp), a potential founder mutation identified in eight Swedish families and one Finnish family with Swedish ancestors. Haplotype analysis confirmed that the Finnish and Swedish families shared a haplotype of between 0.9 and 2.8 Mb. While MLH1 c.2059C > T exists worldwide, the Swedish haplotype was not found among mutation carriers from Germany or France, which indicates a common founder in the Swedish population. The geographic distribution of MLH1 c.2059C > T in Sweden suggests a single, ancient mutational event in the northern part of Sweden.


Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome worldwide, representing 2–4% of the total colorectal cancer burden [1, 2]. Among individuals with a cancer diagnosis at young age the proportion is much higher. Patients have an increased risk for tumors primarily in the proximal colon and the lining of the endometrium, but also in sites such as the stomach, ovaries, small bowel, kidney, urinary tract and brain [3].

LS has an autosomal dominant pattern of inheritance and is caused by germline mutations in any of the DNA mismatch-repair genes MLH1, MSH2, MSH6, PMS2 and EPCAM [4]. Because of incomplete penetrance and variable age of cancer development not all mutation carriers develop cancer. Still, there is up to 70% lifetime risk to come down with early onset colorectal- or endometrial cancer, with the characteristic accelerated development from adenoma to carcinoma [3]. To date just above 3000 sequence variants have been reported for MLH1, MSH2, MSH6 and PMS2 (http://insight-group.org/variants/database, accessed August 25th, 2016). The vast majority are described in MLH1 and MSH2, accounting for approximately 76% of all mutations detected in Swedish Lynch families [5]. Families with a mutation within MLH1 or MSH2 commonly fulfil the Amsterdam I criteria [6] and have a mean age of CRC onset of between 43 and 46 years [7].

Most mutations in the MMR genes are family specific; still some mutations are observed in several different geographic or ethnic populations. Some of them recur in unrelated families because of sequence characteristics that make DNA prone to mutation [8]. Other mutations, so called founder mutations, arose at different occasions in single individuals and fanned out by succeeding generations and therefore show a high frequency in specific ethnic groups. Founder mutations are common in mendelian disorders and have been described in genetically isolated populations as well as in populations with a migratory history [9]. To date, at least 55 LS-associated founder mutations have been identified [8]. Examples are the MLH1 exon 16 deletion and the MLH1 substitution c.454-1G>A, two mutations that together account for up to 50% of LS in the eastern part of Finland [10]. Other examples are the MSH2 c.1906G>C mutation, that accounts for about 20% of all cases of LS in Ashkenazi Jews [11], and the American founder in MLH1 c.589-2A>G [12].

For several LS-associated founder mutations, a common origin has been verified on the basis of shared haplotypes. Moreover, the regional distribution of a mutation can suggest the origin of the mutation. In Sweden three MMR founder mutations have previously been reported; two substitutions in MSH2 [13] and one frameshift mutation in PMS2 [14]. In this study, we have analyzed the disease associated haplotype of the MLH1 missense mutation c.2059C>T, detected in ten families of Swedish origin [5]. This mutation was first reported in Poland by Jakubowska in 2001 [15] and classified as pathogenic in 2013 [16], and has been detected in geographically diverse populations such as Japan, Australia, Germany, Spain and Italy. Our aim was to determine whether the Swedish LS families shared disease associated haplotype, and if so, investigate if this haplotype was present also in other families, from other countries, carrying the same mutation.

Materials and methods


Families from Stockholm County, Sweden, with suspected LS were referred to the Department of Clinical Genetics at the Karolinska University Hospital in Stockholm. After genetic counseling, suspected mutation carriers voluntarily took part in genetic screening of the MMR genes, performed as described [17]. Ten families were found to carry the MLH1 c.2059C>T variant in Sweden [5]. Eight of those were identified at the Karolinska University Hospital in Stockholm between 1994 and 2015, and were consequently enrolled in this study (clinical data presented in Table 1). In addition, two mutation carriers (brothers) from Finland were included, as well as three families from Germany and one family from France. The Finnish family has Swedish ancestry, originating from an area close to the Swedish border in the northern part of Finland. Medical histories and pedigrees were collected from the Swedish families by direct interviews of probands or other family members. Tumor diagnoses were confirmed by pathology reports or hospital records, and age at cancer diagnoses were recorded for the individuals affected. Clinical information regarding the French and German families was available to some extent, while such information was missing for the Finnish family.

Table 1 Clinical features of the Swedish families carrying the MLH1 c.2059C>T (p.Arg687Trp) mutation

Patients and TaqMan analysis in prevalence study

The case cohort in the prevalence study was composed of 2982 consecutive CRC patients which were enrolled in a national study. Patients underwent surgery in Stockholm or Uppsala between 2004 and 2009. They were interviewed by the same person about their family history of colorectal cancer and other malignancies. Cancer in first- and second-degree relatives and cousins was recorded, as well as tumour location, sex and age of the index-patients based on the medical records. All tumours were evaluated directly after surgery by a local pathologist. The control cohort was composed of 1610 anonymous blood donors from the same geographic region as the CRC patients, including 448 spouses to the CRC patients who did not have cancer and no family history of cancer. Screening of the c.2059C>T mutation in the colon cancer cases and control group were performed using TaqMan SNP Genotyping Assay (Applied Biosystems, Foster City, CA) according to the manufacturer´s instructions.

Haplotype analysis

Haplotype analysis was initially performed in one selected family (Family 1552) with more than three known mutation carriers spanning over more than two generations, in order to determine the shared haplotype carrying the disease associated allele. In this family, three individuals were genotyped. In four Swedish families two individuals were genotyped to verify the disease haplotype (families 1894, 765, 1197 and 2143). In the remaining three Swedish families (19, 1517 and F0009520) only the index case was available for genotyping. Two individuals (brothers) from a Finnish family carrying the MLH1 c.2059C>T mutation (family 9) were genotyped. Regarding the French family (family 10) and the three German families (family 11–13) with this mutation, only the index case was available for genotyping.

Genomic DNA from the mutation carriers were initially analyzed using 19 polymorphic microsatellite markers surrounding the MLH1 gene, located on chromosome 3p22.2 (D3S1263, D3S2338, D3S1266, D3S3518, D3S1619, D3S1612, D3D3512, D3S1277, D3S3718, D3S2411, D3S1561, D3S1611, D3S2417, D3S3623, D3S1298, D3S3939, D3S1260, D3S3521 and D3S1289). The markers were selected using the UCSC database (http://genome.ucsc.edu/), human assembly GRCh37. Markers were viewed using full view of STS (sequence-tagged site) markers in track “Mapping and sequencing”. Polymorphic markers, primarily markers in the deCode database were highlighted under STS markers track settings. Markers in the investigated region (11.5–54.5 Mb according to human assembly GRCh37) were selected. These markers span a genomic region of 43.0 Mb with the MLH1 c.2059C>T (p.Arg687Trp) mutation (37.09 Mb) situated between the markers D3S1611 (37.07 Mb) and D3S2417 (37.43 Mb). When a common haplotype was found in the Swedish families, only the shared genomic region was further analyzed in the Finnish, French and three German families. Primers were pooled and amplified using Type-it Microsatellite PCR Kit according to the manufacturer’s instructions (QIAGEN, Hilden, Germany). PCR-products were analyzed using 3500xL Genetic Analyzer and GeneMapper v5 according to the manufacturer’s protocol (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA).

The local Ethics Committee at Karolinska Institutet has approved this study, which followed the tenets of the Declaration of Helsinki.


Clinical data

Eight families carrying the MLH1 c.2059C>T mutation were identified at the Karolinska University Hospital in Stockholm. All families are, to ours and to the families understanding, unrelated. Genetic counseling was sought due to suspicion of inherited cancer and the number of family members in each pedigree varied considerably, as well as the number of genetically tested individuals. The clinical data is summarized in Table 1. There were 29 colorectal cancers in 28 patients and two endometrial cancers in two patients. In addition, there was one patient with ovarian cancer. The first CRC was diagnosed at a median age of 58.5 years (mean 55.5 years, range 31–80 years) and the first EC was diagnosed at a median age of 65.5 years (mean 65.5 years, range 53–78 years). One woman with CRC also developed EC, in which the CRC preceded the EC by 18 years. Two men with CRC also had other malignancies, including prostate cancer in one patient and malignant melanoma in the other.

Prevalence of MLH1 c.2059C>T

Among 1610 normal controls, none were carriers of the mutation. Within the cohort of CRC cases, only one individual was a carrier of the mutation (1/2983) and this family (Family 2143) was included in our study. The index patient was first diagnosed with CRC cancer when she was 60 and had turned 72 by the time of this study. Her sister passed away at an age of 69 suffering from lung and liver cancer (Table 1). Only the index patient and one of her two daughters were genetically tested and proven to be mutation carriers.

Outcome of haplotype analysis

In order to determine the haplotype that carried the mutated allele, haplotype analysis was initially performed in a family with more than three known carriers, spanning over more than two generations. Figure 1 displays the shared haplotype and the relation between the analyzed individuals. Based on data from one individual each from seven unrelated Swedish families (Families 1552, 1894, 19, 765, 1197, 1517, 2143), we found a shared haplotype of about 0.9–2.8 Mb (minimum and maximum distance respectively) within the markers D3S1277 and D3S2417 surrounding MLH1 (human assembly GRCh37, haplotype depicted in Table 2). We then proceeded to analyze this common haplotype in the Finnish (Family 9), the French (Family 10), and the three German families (Families 11–13) as well as one additional Swedish family (Family F0009520) and discovered that the Finnish family and the additional Swedish family shared a haplotype with the Swedish families, while the German and French families shared alleles at some locations but did not share the Swedish haplotype (Table 2).

Fig. 1

Analyzed markers on chromosome 3p22 in family 1552. The disease associated haplotype is marked with a box and in bold letters. Individual with a black dot indicates this is a verified mutation carrier, while a non filled dot indicates a verified non-mutation carrier

Table 2 Markers analyzed in eight Swedish families (1552, 1894, 19, 765, 1197, 1517, 2143 and F0009520), one Finnish family (9), one French family (10) and three German families (11–13)


LS is an autosomal dominantly inherited cancer syndrome with high penetrance, characterized by primarily early onset colorectal and endometrial cancer. The syndrome is caused by inherited mutations in any of the five MMR genes MLH1, MSH2, MSH6, EPCAM or PMS2. A number of pathogenic founder mutations have been described in those genes, which are shared by apparently unrelated families that inherited them from a common ancestor. In this study, we have identified a shared haplotype of 0.9–2.9 Mb in eight Swedish families and one Finnish family with Swedish ancestry using 19 microsatellite polymorphic markers surrounding the Lynch syndrome associated mutation MLH1 c.2059C>T, (p.Arg687Trp). At marker DS31277, family 19 carried the disease allele 271 instead of the common 265 allele (Table 2). Family 1552 shows a recombination event between marker D3S1611 and D3S2417. Since the downstream as well as upstream alleles of these families were consistent with the founder alleles in the common haplotype, this might indicate mutation events rather than a recombination event and thus would implicate that the shared haplotype is larger than 2.9 Mb. Nonetheless, the alleles shared by the Swedish and Finnish family are at a genomic segment of a minimum of 0.9–2.8 Mb.

The earliest verified case in seven of the Swedish families was in the nineteenth century and occurred in individuals from a geographical area in the middle-north of Sweden, except for one family which had ancestors from the very north part of Sweden, as did the Finnish family. Noteworthy, there are two additional Swedish families previously identified with this mutation [5] living in the northern part of Sweden. However, samples from these families were not available for haplotype analysis at the time of this study.

In family number 19, 1197 and 2143, the MLH1 c.2059C>T mutation does not perfectly segregate with cancer diagnosis (Table 1). Mutations causing Lynch syndrome are indeed characterized by heterogeneity both in penetrance and phenotype, however in these families this segregation pattern is probably due to random events of sporadic cancer, and in some cases due to young age in known mutation carriers. Importantly, the contribution of MMR mutations to Lynch syndrome associated cancer is a function of each patient’s genetic and environmental background, influencing mutation penetrance. Therefore, a more limited genetic variability would be beneficial in the study of cancer risks. This can be offered in members of founder populations such as MLH1 c.2059C>T, and might aid in more personalized cancer-risk counseling for those patients.

The MLH1 c.2059C>T mutation occurs independently both in Europe [18,19,20], Asia [21] and Australia [22, 23], suggesting that globally this is a recurring mutation, while in Sweden it seems to represent a founder mutation which arose in a common ancestor that existed several generations back. Genetic mutations situated in mutational hotspots might actually be prevalent in several populations, but can still display a founder effect in specific populations. This is exemplified by two deletions in MSH2 detected in Portuguese families that shared disease associated haplotype. On the contrary, in families from Germany, Scotland, England and Argentina carrying the same mutation the haplotype was different [24, 25]. The authors explained this recurrence by a short repeated sequence motif upstream the mutation that created a mutational hotspot in MSH2. A similar case is a splice site mutation in MSH2 that was spread by a founder in Newfoundland, but later turned out to occur in several other populations [26]. This mutation is common and arises repeatedly de novo due to sequence features affecting replication, a mononucleotide tract of adenines, with Newfoundland carriers sharing haplotype as opposed to carriers in Hong Kong, Japan, Italy or England [27].

The genome aggregation database (gnomAD, http://gnomad.broadinstitute.org/) [28] reports a carrier frequency of approximately 1/67,000 in the European population (including the Finnish population) for MLH1 c.2059C>T. In gnomAD the variant has also been found three times in the south Asian population as well as once in the African population, giving a total average carrier frequency of 1/25,000 combining analyzed populations in this database.

In an isolated, growing population the effect of genetic drift/chance is more pronounced than in a relatively heterogeneous population such as the Swedish. Still, there are examples of founder mutations that occur rarely in such populations apart from MLH1 c.2059C>T, e.g. the mutation c.589-2A>G that affect splicing in MLH1. This mutation was detected in ten American and three Italian families, with the American and Italian families having different haplotypes [12].

In conclusion, we show that MLH1 c.2059C>T mutation is a Swedish founder mutation with a probable origin in a single founder individual in the north of Sweden, whose descendants have migrated southwards in Sweden as well as across the border to Finland. As common genetic variation (e.g. single nucleotide polymorphisms) might also influence disease risks in MMR mutation carriers, information regarding shared haplotypes among founder mutations carriers is useful for more precise risk estimation in the near future. Phenotypic variation in LS among families carrying the same founder mutations has been reported [29], still we emphasize the importance of clinical characterization of founder mutations and additional epidemiologic studies on LS cohorts carrying founder mutations when striving towards mutation-specific counseling and a possibility to improve clinical care.


  1. 1.

    Sehgal R, Sheahan K, O’Connell PR, Hanly AM, Martin ST, Winter DC (2014) Lynch syndrome: an updated review. Genes 5:497–507

    Article  Google Scholar 

  2. 2.

    Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet 76:1–18

    CAS  Article  Google Scholar 

  3. 3.

    Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G et al (2013) Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut 62:812–823

    CAS  Article  Google Scholar 

  4. 4.

    Ligtenberg MJ, Kuiper RP, Chan TL, Goossens M, Hebeda KM, Voorendt M, Lee TY, Bodmer D, Hoenselaar E, Hendriks-Cornelissen SJ et al (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3′ exons of TACSTD1. Nat Genet 41:112–117

    CAS  Article  Google Scholar 

  5. 5.

    Lagerstedt-Robinson K, Rohlin A, Aravidis C, Melin B, Nordling M, Stenmark-Askmalm M, Lindblom A, Nilbert M (2016) Mismatch repair gene mutation spectrum in the Swedish Lynch syndrome population. Oncol Rep 36(5):2823–2835

    CAS  Article  Google Scholar 

  6. 6.

    Vasen HF, Watson P, Mecklin JP, Lynch HT (1999) New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 116:1453–1456

    CAS  Article  Google Scholar 

  7. 7.

    Lynch HT, Snyder CL, Shaw TG, Heinen CD, Hitchins MP (2015) Milestones of Lynch syndrome: 1895–2015. Nat Rev Cancer 15:181–194

    CAS  Article  Google Scholar 

  8. 8.

    Ponti G, Castellsague E, Ruini C, Percesepe A, Tomasi A (2015) Mismatch repair genes founder mutations and cancer susceptibility in Lynch syndrome. Clin Genet 87:507–516

    CAS  Article  Google Scholar 

  9. 9.

    Zeegers MP, van Poppel F, Vlietinck R, Spruijt L, Ostrer H (2004) Founder mutations among the Dutch. Eur J Hum Genet 12:591–600

    CAS  Article  Google Scholar 

  10. 10.

    Nystrom-Lahti M, Kristo P, Nicolaides NC, Chang SY, Aaltonen LA, Moisio AL, Jarvinen HJ, Mecklin JP, Kinzler KW, Vogelstein B et al (1995) Founding mutations and Alu-mediated recombination in hereditary colon cancer. Nat Med 1:1203–1206

    CAS  Article  Google Scholar 

  11. 11.

    Foulkes WD, Thiffault I, Gruber SB, Horwitz M, Hamel N, Lee C, Shia J, Markowitz A, Figer A, Friedman E et al (2002) The founder mutation MSH2*1906G–>C is an important cause of hereditary nonpolyposis colorectal cancer in the Ashkenazi Jewish population. Am J Hum Genet 71:1395–1412

    CAS  Article  Google Scholar 

  12. 12.

    Tomsic J, Liyanarachchi S, Hampel H, Morak M, Thomas BC, Raymond VM, Chittenden A, Schackert HK, Gruber SB, Syngal S et al (2012) An American founder mutation in MLH1. Int J Cancer 130:2088–2095

    CAS  Article  Google Scholar 

  13. 13.

    Cederquist K, Emanuelsson M, Wiklund F, Golovleva I, Palmqvist R, Gronberg H (2005) Two Swedish founder MSH6 mutations, one nonsense and one missense, conferring high cumulative risk of Lynch syndrome. Clin Genet 68:533–541

    CAS  Article  Google Scholar 

  14. 14.

    Clendenning M, Senter L, Hampel H, Robinson KL, Sun S, Buchanan D, Walsh MD, Nilbert M, Green J, Potter J et al (2008) A frame-shift mutation of PMS2 is a widespread cause of Lynch syndrome. J Med Genet 45:340–345

    CAS  Article  Google Scholar 

  15. 15.

    Jakubowska A, Gorski B, Kurzawski G, Debniak T, Hadaczek P, Cybulski C, Kladny J, Oszurek O, Scott RJ, Lubinski J (2001) Optimization of experimental conditions for RNA-based sequencing of MLH1 and MSH2 genes. Hum Mutat 17:52–60

    CAS  Article  Google Scholar 

  16. 16.

    Thompson BA, Spurdle AB, Plazzer JP, Greenblatt MS, Akagi K, Al-Mulla F, Bapat B, Bernstein I, Capella G, den Dunnen JT et al (2014) Application of a 5-tiered scheme for standardized classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat Genet 46:107–115

    CAS  Article  Google Scholar 

  17. 17.

    Lagerstedt Robinson K, Liu T, Vandrovcova J, Halvarsson B, Clendenning M, Frebourg T, Papadopoulos N, Kinzler KW, Vogelstein B, Peltomaki P et al (2007) Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst 99:291–299

    Article  Google Scholar 

  18. 18.

    Nilbert M, Wikman FP, Hansen TV, Krarup HB, Orntoft TF, Nielsen FC, Sunde L, Gerdes AM, Cruger D, Timshel S et al (2009) Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population. Fam Cancer 8:75–83

    Article  Google Scholar 

  19. 19.

    Hardt K, Heick SB, Betz B, Goecke T, Yazdanparast H, Kuppers R, Servan K, Steinke V, Rahner N, Morak M et al (2011) Missense variants in hMLH1 identified in patients from the German HNPCC consortium and functional studies. Fam Cancer 10:273–284

    CAS  Article  Google Scholar 

  20. 20.

    Kurzawski G, Suchy J, Lener M, Klujszo-Grabowska E, Kladny J, Safranow K, Jakubowska K, Jakubowska A, Huzarski T, Byrski T et al (2006) Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study). Clin Genet 69:40–47

    CAS  Article  Google Scholar 

  21. 21.

    Furukawa T, Konishi F, Shitoh K, Kojima M, Nagai H, Tsukamoto T (2002) Evaluation of screening strategy for detecting hereditary nonpolyposis colorectal carcinoma. Cancer 94:911–920

    Article  Google Scholar 

  22. 22.

    Schofield L, Grieu F, Goldblatt J, Amanuel B, Iacopetta B (2012) A state-wide population-based program for detection of lynch syndrome based upon immunohistochemical and molecular testing of colorectal tumours. Fam Cancer 11:1–6

    CAS  Article  Google Scholar 

  23. 23.

    Arnold S, Buchanan DD, Barker M, Jaskowski L, Walsh MD, Birney G, Woods MO, Hopper JL, Jenkins MA, Brown MA et al (2009) Classifying MLH1 and MSH2 variants using bioinformatic prediction, splicing assays, segregation, and tumor characteristics. Hum Mutat 30:757–770

    CAS  Article  Google Scholar 

  24. 24.

    Pinheiro M, Pinto C, Peixoto A, Veiga I, Mesquita B, Henrique R, Lopes P, Sousa O, Fragoso M, Dias LM et al (2013) The MSH2 c.388_389del mutation shows a founder effect in Portuguese Lynch syndrome families. Clin Genet 84:244–250

    CAS  Article  Google Scholar 

  25. 25.

    Pinheiro M, Pinto C, Peixoto A, Veiga I, Mesquita B, Henrique R, Baptista M, Fragoso M, Sousa O, Pereira H et al (2011) A novel exonic rearrangement affecting MLH1 and the contiguous LRRFIP2 is a founder mutation in Portuguese Lynch syndrome families. Genet Med 13:895–902

    CAS  Article  Google Scholar 

  26. 26.

    Desai DC, Lockman JC, Chadwick RB, Gao X, Percesepe A, Evans DG, Miyaki M, Yuen ST, Radice P, Maher ER et al (2000) Recurrent germline mutation in MSH2 arises frequently de novo. J Med Genet 37:646–652

    CAS  Article  Google Scholar 

  27. 27.

    Froggatt NJ, Joyce JA, Davies R, Gareth D, Evans R, Ponder BA, Barton DE, Maher ER (1995) A frequent hMSH2 mutation in hereditary non-polyposis colon cancer syndrome. Lancet 345:727

    CAS  Article  Google Scholar 

  28. 28.

    Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, O’Donnell-Luria AH, Ware JS, Hill AJ, Cummings BB et al (2016) Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285–291

    CAS  Article  Google Scholar 

  29. 29.

    Peltomaki P, Gao X, Mecklin JP (2001) Genotype and phenotype in hereditary nonpolyposis colon cancer: a study of families with different vs. shared predisposing mutations. Fam Cancer 1:9–15

    CAS  Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Kristina Lagerstedt-Robinson.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

von Salomé, J., Liu, T., Keihäs, M. et al. Haplotype analysis suggest that the MLH1 c.2059C > T mutation is a Swedish founder mutation. Familial Cancer 17, 531–537 (2018). https://doi.org/10.1007/s10689-017-0067-x

Download citation


  • Lynch syndrome
  • MLH1
  • Missense mutation
  • Founder mutation
  • Haplotype